Dias Rafael Pessoa Porpino, Rodrigues Jose Luiz Teixeira, Jabour Maíra Said Dias, Albuquerque Raíssa de Oliveira E, Friedrich Henrique de Almeida, Westphalen Michele Sander, Caropreso Carlos Alberto
Department of Ophthalmology, Otorhinolaryngology, Head and Neck Surgery, Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Int Arch Otorhinolaryngol. 2025 Apr 22;29(2):1-6. doi: 10.1055/s-0044-1801319. eCollection 2025 Apr.
Thick-skinned patients are prevalent in the general population worldwide and represent a challenge for the rhinoplasty surgeon. The use of oral isotretinoin before and/or after surgery is a possible adjuvant treatment that can facilitate intraoperative management and improve results in the postoperative stages; however, there are still questions about its effects in the long-term. To evaluate the advantages and best practices for orally administrated isotretinoin in thick-skin rhinoplasty based on the current literature. An advanced search was conducted until August 31st, 2023, on the PubMed, Cochrane Library, ClinicalTrials.gov, Embase, and LILACS databases with the keywords and . Sixteen articles were reviewed and 4 met the inclusion criteria, with a total of 371 patients. Meta-analysis of the data collected was not possible due to heterogeneity among papers. Isotretinoin can be a safe drug, and its use in rhinoplasty varies widely, although all studies reported a low-dose oral regime for up to 6 months. The medication use is well-established in thick-skin rhinoplasty. Small doses after the procedure can improve patient satisfaction and the quality and thickness of the skin in the first 6 months of postsurgery. After 6 months, studies with a control group did not show a significant difference in patient satisfaction rates. A strong framework and specific surgical maneuvers may be more important than isotretinoin for better outcomes in thick-skin rhinoplasty.
厚皮患者在全球普通人群中普遍存在,这对鼻整形外科医生来说是一项挑战。在手术前和/或手术后使用口服异维A酸是一种可能的辅助治疗方法,它可以便于术中管理并改善术后效果;然而,关于其长期效果仍存在疑问。
为了根据当前文献评估口服异维A酸在厚皮鼻整形中的优势和最佳实践。
截至2023年8月31日,在PubMed、Cochrane图书馆、ClinicalTrials.gov、Embase和LILACS数据库中进行了高级搜索,关键词为[具体关键词未给出]。共审查了16篇文章,4篇符合纳入标准,共有371例患者。由于各论文之间存在异质性,无法对收集到的数据进行荟萃分析。
异维A酸可能是一种安全的药物,其在鼻整形中的应用差异很大,尽管所有研究都报告了长达6个月的低剂量口服方案。该药物在厚皮鼻整形中的应用已得到充分证实。术后小剂量使用可以提高患者满意度,并在术后前6个月改善皮肤质量和厚度。6个月后,有对照组的研究未显示患者满意度有显著差异。对于厚皮鼻整形取得更好的效果,一个强大的框架和特定的手术操作可能比异维A酸更重要。